# US 2006/0223819 A1 · Quinoline Derivatives as NK-3 Antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0223819 A1
- Document ID: US20060223819A1
- Status: Published application
- Kind: A1
- Application number: 11/425,508
- Filed: 2006-06-21
- Published: 2006-10-05
- Earliest claimed: 2000-11-28
- Assignees: GlaxoSmithKline S.P.A. & Laboratoire; GlaxoSmithKline LLC
- Inventors: Carlo Farina; Stefania Gagliardi; Giuseppe Giardina; Mario Grugni; Marisa Martinelli; Guy Marguerite Nadler
- Web page: https://patentgrep.com/patent/US20060223819A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 11/14: Antitussive agents
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 27/02: Ophthalmic agents
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 31/18: for HIV
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 215/52: with aryl radicals attached in position 2
- C07D 409/14: containing three or more hetero rings
- C07D 493/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Certain compounds of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof: a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

## Claims

### Claim 1

A compound of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof:
wherein:
R1 is H or alkyl;
R2 is aryl or cycloalkyl or heteroaryl, optionally substituted one or more times by alkyl, OH or alkoxy;
R3 is H or alkyl or cycloalkyl or cycloalkylalkyl, optionally substituted one or more times by hydroxy or by one or more fluorines;
R4 is H, or —R8R9 where R8 is optionally substituted one or more times by R′3, or R19;
R8 is alkyl or alkenyl;
R9 is S(O2)R10, S(O2)OR10, ONO, C(O)OR10, C(O)NR′1R′2, or CN;
R10 is H, alkyl, aryl or cycloalkyl;
R11 and R12 are independently selected from H and alkyl;
R13 is R14 or —R′4R′5;
R14 is alkyl, aryl, cycloalkyl, arylalkyl, or a five-, six-, seven- or eight-membered heterocyclic ring comprising one or more heteroatoms selected from N, O and S;
R15 is alkyl or —R′6COOR′7;
R16 is a single bond or alkyl;
R17 is H or alkyl;
R18 is H or up to three oxo substituents;
R19 is R20 or —R2OR21;
R20 is alkyl, alkenyl or a single bond;
R21 is OH, aryl, cycloalkyl or a saturated heterocyclic ring comprising one or more heteroatoms selected from N, O and S;
R5 is a alkyl, cycloalkyl, cycloalkylalkyl, aryl, or single or fused ring aromatic heterocyclic group, which group may be substituted one or more times by halo, hydroxy, alkyl or alkyl substituted one or more times by halo or hydroxy;
R6 represents H or up to three substituents independently selected from the list consisting of: alkyl, alkenyl, aryl, alkoxy or a hydroxylated derivative thereof, hydroxy, halogen, nitro, cyano, carboxy, alkylcarboxy, alkylcarboxyalkyl, haloalkyl such as trifluoromethyl, amino or mono- or di-alkylamino; or R6 represents a bridging moiety which is arranged to bridge two adjacent ring atoms, which bridging moiety comprises alkyl or dioxyalkylene;
R7 is H or halo;
a is 1-6; and
any of R2, R5, R8, R10, R11, R12, R14, R16, R17 and R21 may optionally be substituted one or more times by halo, hydroxy, amino, cyano, nitro, carboxy or oxo;
subject to the proviso that said compound is not a compound wherein R7 represents H, R5 represents unsubstituted phenyl, R18 is H, and R1, R2, R3 and R4 are one of the following combinations:
a
R4
R6
1
H
1
H
H
1
H
H
1
H
2
H
3
H
4
H
3
H
2
H
2
H
3
OMe
1
H
1
H
1
H
1
H
1
H
1
H
1
Et
H
1
Me
H
1
H
2
Me
H
1
Et
H
1
H
3
OH

### Claim 2 (depends on 1)

A compound as claimed in claim 1, wherein R3 represents methyl, ethyl, isopropyl, cyclopropyl, hydroxymethyl or hydroxyethyl.

### Claim 3 (depends on 1)

A compound as claimed in claim 1, wherein R2 represents phenyl or cyclohexyl.

### Claim 4 (depends on 3)

A compound as claimed in claim 3, wherein R2 represents phenyl which is meta- or para-substituted once by —OMe or —OH.

### Claim 5 (depends on 1)

A compound as claimed in claim 1, wherein R1 is hydrogen or methyl.

### Claim 6 (depends on 1)

A compound as claimed in claim 1, wherein R5 is phenyl which is unsubstituted or which is substituted one or more times by halo such as fluoro and/or by haloalkyl such as trifluoromethyl.

### Claim 7 (depends on 1)

A compound as claimed in claim 1, wherein R5 is a heterocyclic ring, such as an unsaturated heterocyclic ring, comprising at least one heteroatom such as S.

### Claim 8 (depends on 7)

A compound as claimed in claim 7, wherein R5 is

### Claim 9 (depends on 1)

A compound as claimed in claim 1, wherein R7 represents hydrogen.

### Claim 10 (depends on 1)

A compound as claimed in claim 1, wherein R6 represents hydrogen or one or more substituents selected from fluoro, chloro, bromo or trifluoromethyl.

### Claim 11 (depends on 10)

A compound as claimed in claim 10, wherein each of said one or more substituents is respectively positioned at the 5′, 6′, 7′ or 8′ position around the quinoline ring of said compound.

### Claim 12 (depends on 1)

A compound as claimed in claim 1, wherein R6 represents one ring substituent, which is hydroxy, alkoxy such as methoxy or ethoxy or a hydroxylated derivative thereof, alkoxycarboxylate such as methoxycarboxylate or ethoxycarboxylate or an esterified derivative thereof such as methoxyethanoate ethoxyethanoate, or alkoxyamido such as methoxyamido or ethoxyamido.

### Claim 13 (depends on 12)

A compound as claimed in claim 12, wherein said one ring substituent is located at the 6 or 7 position around the quinoline ring of said compound.

### Claim 14 (depends on 1)

A compound as claimed in claim 1, wherein a is 1, 2 or 3.

### Claim 15 (depends on 1)

A compound as claimed in claim 1, wherein R4 is hydrogen.

### Claim 16 (depends on 1)

A compound as claimed in claim 1, wherein R8 is methyl, ethyl, ethenyl or propenyl.

### Claim 17 (depends on 1)

A compound as claimed in claim 1, wherein R9 is C(O)OH or C(O)NH2-18. A compound as claimed in claim 1, wherein R9 is S(O2)R10, S(O2)OR10, or C(O)OR10, and R10 is phenyl, methyl or ethyl.

### Claim 18 (depends on 1)

A compound as claimed in claim 1, wherein R9 is S(O2)R10, S(O2)OR10, or C(O)OR10, and R10 is phenyl, methyl or ethyl.

### Claim 19 (depends on 1)

A compound as claimed in claim 1, wherein R9 is C(O)NR11R12 and each of R10 and R11 is the same one of methyl or ethyl.

### Claim 20 (depends on 1)

A compound as claimed in claim 1, wherein R4 is branched or linear R8(R13)R9, R13 is R14 and R14 is C1-6 alkyl, or phenyl, or phenylmethyl, or phenylethyl.

### Claim 21 (depends on 1)

A compound as claimed in claim 1, wherein R4 is branched or linear R8(R13)R9, R13 is R14R15, and R14 is a five- or six-membered saturated heterocyclic ring.

### Claim 22 (depends on 21)

A compound as claimed in claim 21, wherein said heterocyclic ring comprises one or more N atoms.

### Claim 23 (depends on 21)

A compound as claimed in claim 21, wherein said heterocyclic ring is N-linked to said R8.

### Claim 24 (depends on 1)

A compound as claimed in claim 1, wherein R4 is branched or linear R8(R13)R9, R13 is —R14R15, and R14 is C1-6 alkyl, or phenyl, or phenylmethyl, or phenylethyl.

### Claim 25 (depends on 1)

A compound as claimed in claim 1, wherein R15 is hydrogen, methylethanoate, ethylethanoate, propylethanoate or butylethanoate.

### Claim 26 (depends on 1)

A compound as claimed in claim 1, wherein R20 is a single bond and R21 is aryl such as phenyl.

### Claim 27 (depends on 1)

A compound as claimed in claim 1, wherein R20 is straight chain alkyl such as methyl, ethyl or propyl, and R21 is OH, aryl, or a saturated heterocyclic ring comprising one or more N heteroatoms.

### Claim 28 (depends on 1)

A compound as claimed in claim 1, wherein R18 is H.

### Claim 29 (depends on 1)

A compound as claimed in claim 1, wherein R18 represents one or more oxo substituents.

### Claim 30 (depends on 29)

A compound as claimed in claim 29, wherein R18 represents one oxo substituent which is positioned at the 3′, 5′ or 6′ position around the piperazine ring of said compound.

### Claim 31 (depends on 29)

A compound as claimed in claim 29, wherein R18 represents two oxo substituents which are respectively positioned at the 3′ and 5′ or at the 3′ and 6′ positions around the piperazine ring of said compound.

### Claim 32 (depends on 1)

A compound as claimed in claim 1, which is selected from the following:

### Claim 33 (depends on 1)

A process for the preparation of a compound of formula (I) according to claim 1, or a salt thereof and/or a solvate thereof, which process comprises reacting a compound of formula (II) or an active derivative thereof:
wherein R′5, R′6, and R′7 are R5, R6, and R7 respectively as defined in relation to formula (I) or a group convertible to R5, R6, and R7 respectively, and Y′ is a group of formula (Y) or a group convertible thereto
wherein R4 and R18 are defined as in relation to formula (I) above, with a compound of formula (III):
wherein R′1, R′2 and R′3 are R1, R2 and R3 as defined for formula (I) or a group or atom convertible to R1, R2 and R3 respectively; to form a compound of formula (Ib):
wherein R′1, R′2, R′3, R′5, R′6, R′7 and Y′ are as defined above, and thereafter carrying out one or more of the following optional steps:
(i) converting any one of R′1, R′2, R′3, R′5, R′6, R′7 and Y′ to R1, R2, R3, R5, R6, R7 and Y respectively as required, to obtain a compound of formula (I);
(ii) converting a compound of formula (I) into another compound of formula (I); and
(iii) preparing a salt of the compound of formula (I) and/or a solvate thereof.

### Claim 34 (depends on 1)

A process for the preparation of a compound of formula (I) according to claim 1, wherein a is 1, or a salt thereof and/or a solvate thereof, which process comprises reacting a compound of formula (T) or an active derivative thereof:
wherein each of R′1, R′2, R′3, R′5, R′6, and R′7 is R1, R2, R3, R5, R6, or R7 respectively as defined in relation to formula (I) or a group convertible to R1, R2, R3, R5, R6, or R7 respectively, providing that R2 is not an aromatic group, with a compound of formula (W)
wherein R′4 is a group R4 as defined in relation to formula (I) or a protected form thereof or a group convertible thereto, and R18 is a group R18 as defined in relation to formula (I), to form a compound of formula (Ib):
and thereafter carrying out one or more of the following optional steps:
(i) converting any one of R′1, R′2, R′3, R′4, R′5, R′6, and R′7 to R1, R2, R3, R4, R5, R6, and R7 respectively as required, to obtain a compound of formula (I) as claimed in claim 1;
(ii) converting a compound of formula (I) as claimed in claim 1 into another compound of formula (I) as claimed in claim 1; and
(iii) preparing a salt of the compound of formula (I) as claimed in claim 1 and/or a solvate thereof.

### Claim 35 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

### Claim 36

(canceled)

### Claim 37

A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the treatment or prophylaxis of the Primary and Secondary Conditions.

### Claim 38

(canceled)

### Claim 39

A method for the treatment and/or prophylaxis of the Primary and Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective, non-toxic pharmaceutically acceptable amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
